Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel in Advanced Ovarian Cancer
Randomized clinical trial to asses the efficacy of closed abdomen hyperthermia intraperitoneal chemotherapy with paclitaxel in ovarian cancer.
Epithelial Ovarian Cancer
DRUG: HIPEC|PROCEDURE: No HIPEC
Overall survival, From the date of surgery to the date of death or to the end of study (follow up every 6 months till 3 years), every 6 months till 36 months
Progression free survival, From the date of surgery to the date of recurrence or to the end of study (follow up every 6 months till 18 months), follow up every 6 months till 18 months
Post-operative complications, Compare adverse events between study arms, adverse events within 30 days postoperatively (according to NCI criteria, Common Terminology Criteria for AE (CTCAE))
Randomized clinical trial performed in woman with epithelial primary ovarian cancer (stage FIGO II, III and IV) or tumor recurrence. A cytoreductive surgery will be perform in all of the patients include in the trial, and it will be assign at randomization:

* HIPEC-arm: cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with paclitaxel (175 mg / m2) for 60 minutes at a temperature of 42-43ยบ degrees; followed by postoperative systemic IV chemotherapy with carboplatin (AUC=6) and paclitaxel (175 mg/m2) for 6 cycles.
* No HIPEC-arm: Cytoreductive surgery followed by postoperative systemic IV chemotherapy with carboplatin (AUC=6) and paclitaxel (175 mg/m2) for 6 cycles.